I’m Greta Klejborowska and I’m a Postdoctoral Research Fellow in the Medicinal Chemistry Research Group, led by Prof. Koen Augustyns. My research is focused on the development of novel ferroptosis inhibitors. But what exactly is ferroptosis and why is it important to block or inhibit it?
During her PhD research in Biomedical Sciences, Emilie Logie aimed to find new treatment options to overcome therapy resistance in the blood cancer multiple myeloma. Together with Professor Wim Vanden Berghe, her supervisor at the Proteinchemistry, Proteomics and Epigenetic Signalling (PPES) lab, Emilie used and combined different molecular techniques to identify new ways for treating therapy-resistant multiple myeloma cancers.
Prof. Tom Vanden Berghe and Prof. Koen Augustyns have received a 1.7M euro FWO-SBO grant to pave the way for a ferroptosis spin-off company. Together with a KULeuven team of transplantation surgeons, they will introduce ferroptosis inhibitors into the clinical practice of organ transplantation.